Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,252 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
New molecular targets in bone metastases.
Santini D, Galluzzo S, Zoccoli A, Pantano F, Fratto ME, Vincenzi B, Lombardi L, Gucciardino C, Silvestris N, Riva E, Rizzo S, Russo A, Maiello E, Colucci G, Tonini G. Santini D, et al. Among authors: rizzo s. Cancer Treat Rev. 2010 Nov;36 Suppl 3:S6-S10. doi: 10.1016/S0305-7372(10)70013-X. Cancer Treat Rev. 2010. PMID: 21129612 Review.
Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer: a single-center phase 2 trial.
Vincenzi B, Santini D, Russo A, Spoto C, Venditti O, Gasparro S, Rizzo S, Zobel BB, Caricato M, Valeri S, Coppola R, Tonini G. Vincenzi B, et al. Among authors: rizzo s. Cancer. 2009 Oct 15;115(20):4849-56. doi: 10.1002/cncr.24540. Cancer. 2009. PMID: 19626652 Free article. Clinical Trial.
PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients.
Vincenzi B, Santini D, Perrone G, Graziano F, Loupakis F, Schiavon G, Frezza AM, Ruzzo AM, Rizzo S, Crucitti P, Galluzzo S, Zoccoli A, Rabitti C, Muda AO, Russo A, Falcone A, Tonini G. Vincenzi B, et al. Among authors: rizzo s. J Cell Physiol. 2012 Mar;227(3):927-33. doi: 10.1002/jcp.22801. J Cell Physiol. 2012. PMID: 21503888
The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials.
Rizzo S, Galvano A, Pantano F, Iuliani M, Vincenzi B, Passiglia F, Spoto S, Tonini G, Bazan V, Russo A, Santini D. Rizzo S, et al. Crit Rev Oncol Hematol. 2017 Dec;120:227-233. doi: 10.1016/j.critrevonc.2017.09.008. Epub 2017 Oct 16. Crit Rev Oncol Hematol. 2017. PMID: 29110971 Review.
How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials.
Santini D, Galvano A, Pantano F, Incorvaia L, Rizzo S, Vincenzi B, Castellana L, Giuliana G, Guadagni F, Toia F, Tonini G, Russo A, Badalamenti G, Bazan V. Santini D, et al. Among authors: rizzo s. Crit Rev Oncol Hematol. 2019 Oct;142:68-75. doi: 10.1016/j.critrevonc.2019.07.013. Epub 2019 Jul 25. Crit Rev Oncol Hematol. 2019. PMID: 31377434
Biomarkers and efficacy: are we nearly there yet?
Russo A, Rizzo S. Russo A, et al. Among authors: rizzo s. Ann Oncol. 2011 Jul;22(7):1469-1470. doi: 10.1093/annonc/mdr258. Epub 2011 May 5. Ann Oncol. 2011. PMID: 21551003 Free article. No abstract available.
Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC).
Santini D, Schiavon G, Vincenzi B, Cass CE, Vasile E, Manazza AD, Catalano V, Baldi GG, Lai R, Rizzo S, Giacobino A, Chiusa L, Caraglia M, Russo A, Mackey J, Falcone A, Tonini G. Santini D, et al. Among authors: rizzo s. Curr Cancer Drug Targets. 2011 Jan;11(1):123-9. doi: 10.2174/156800911793743600. Curr Cancer Drug Targets. 2011. PMID: 20578980 Free article. Review.
1,252 results